Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study. - Nambu R; Iwama I; Takeuchi I; Hagiwara SI; Etani Y; Kaji E; Yoden A; Kakuta F; Hoshi Y; Tsumura N; Mizuochi T; Kumagai H; et al. (Journal of gastroenterology, 2026)